Skip to main content

Table 5 Univariate analysis of LR, RR, and DM of young breast cancer patients

From: Loco-regional recurrence trend and prognosis in young women with breast cancer according to molecular subtypes: analysis of 1099 cases

Characteristics LR RR DM
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Tumor size   < 0.01   < 0.01   < 0.01
T1 1.0   1.0   1.0  
T2 0.8 (0.5–1.3) 0.40 0.9 (0.5–1.7) 0.85 1.9 (1.3–2.7) < 0.01
T3 2.2 (1.1–4.5) 0.02 3.4 (1.6–7.0) < 0.01 5.7 (3.7–8.7) < 0.01
T4 8.5 (3.3–22.0) < 0.01 9.2 (3.1–27.0) < 0.01 13.7 (7.1–26.5) < 0.01
Stage   < 0.01   < 0.01   < 0.01
I 1.0   1.0   1.0  
II a 1.5 (0.8–2.9) 0.22 0.4 (0.2–1.1) 0.09 2.1 (1.2–3.5) < 0.01
II b 2.0 (1.0–4.3) 0.06 2.0 (0.9–4.5) 0.08 3.4 (1.9–6.0) < 0.01
III a 1.0 (0.4–2.7) 0.92 3.6 (1.7–7.5) < 0.01 6.2 (3.6–10.6) < 0.01
III b 7.8 (1.8–34.3) < 0.01 4.3 (0.6–33.1) 0.16 14.8 (5.5–39.6) < 0.01
III c 3.8 (1.5–9.5) < 0.01 4.1 (1.8–9.1) < 0.01 12.9 (7.6–21.8) < 0.01
LN metastasis   < 0.01   <0.01   < 0.01
N0 1.0   1.0   1.0  
N1 2.3 (1.4–3.7) < 0.01 2.3 (1.1–4.6) 0.02 2.1 (1.5–3.0) < 0.01
N2 1.0 (0.4–2.3) 0.95 5.9 (3.0–11.5) < 0.01 3.8 (2.6–5.6) < 0.01
N3 3.9 (2.1–7.3) < 0.01 6.9 (3.3–14.5) < 0.01 8.1 (5.6–11.8) < 0.01
HG   0.09   0.81   0.21
I 1.0   1.0   1.0  
II 0.6 (0.2–1.6) 0.26 0.7 (0.2–2.4) 0.60 1.9 (0.7–5.3) 0.19
III 1.1 (0.4–3.3) 0.86 1.0 (0.3–3.5) 0.97 2.5 (0.9–7.0) 0.08
Final surgery   0.13   0.30   < 0.01
Mastectomy 1.0   1.0   1.0  
BCS 1.4 (0.9–2.3) 0.13 0.7 (0.4–1.3) 0.30 0.4 (0.3–0.7) < 0.01
ER status   < 0.01   0.16   0.35
Positive 1.0   1.0   1.0  
Negative 2.0 (1.3–3.1) < 0.01 1.6 (1.0–2.7) 0.06 1.2 (0.9–1.6) 0.25
PR status   < 0.01   0.94   0.93
Positive 1.0   1.0   1.0  
Negative 1.9 (1.2–2.9) < 0.01 1.1 (0.7–1.9) 0.72 1.1 (0.8–1.4) 0.71
HER2 status   < 0.01   0.59   < 0.01
Positive 1.0   1.0   1.0  
Negative 0.5 (0.3–0.8) < 0.01 0.8 (0.4–1.4) 0.38 0.6 (0.4–0.8) < 0.01
MS   < 0.01   0.66   < 0.01
HR+/HER2− 1.0   1.0   1.0  
HR+/HER2+ 1.7 (0.8–3.4) 0.15 1.0 (0.4–2.3) 0.94 1.5 (1.0–2.2) 0.06
HR−/HER2+ 3.5 (1.8–6.7) < 0.01 1.7 (0.8–3.9) 0.18 1.9 (1.2–2.9) < 0.01
HR−/HER2− 1.5 (0.8–2.7) 0.20 0.9 (0.4–1.8) 0.73 0.7 (0.5–1.1) 0.15
NACT   0.04   < 0.01   < 0.01
No 1.0   1.0   1.0  
Yes 1.8 (1.0–3.0) 0.04 2.5 (1.4–4.3) < 0.01 2.9 (2.1–3.8) < 0.01
ACT   0.18   0.70   0.29
A- and T-based 1.0   1.0   1.0  
A-based 1.2 (0.7–2.2) 0.47 1.3 (0.7–2.5) 0.48 1.2 (0.8–1.7) 0.42
Radiotherapy   0.20   0.03   < 0.01
No 1.0   1.0   1.0  
Yes 1.1 (0.7–1.8) 0.56 1.9 (1.1–3.3) 0.03 2.5 (1.8–3.5) < 0.01
ET   < 0.01   0.09   0.22
No 1.0   1.0   1.0  
Yes 0.5 (0.3–0.7) < 0.01 0.7 (0.4–1.3) 0.30 1.1 (0.8–1.5) 0.71
OFS   0.52   < 0.01   < 0.01
No 1.0   1.0   1.0  
Yes 1.2 (0.6–2.1) 0.64 3.4 (1.8–6.2) < 0.01 3.7 (2.6–5.3) < 0.01
TT   0.30   0.94   0.14
No 1.0   1.0   1.0  
Yes 1.5 (0.7–3.4) 0.30 0.9 (0.3–2.6) 0.94 1.4 (0.9–2.3) 0.14
  1. UA, univariate analysis; MA, multivariate analysis; HG, histological grade; MS, molecular subtype; NACT, neoadjuvant chemotherapy; ACT, adjuvant chemotherapy; ET, endocrine therapy; TT, trastuzumab therapy
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us

\